Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, B-Cell × Ifosfamide × Clear all

Phase

Phase 2 4 Phase EARLY_PHASE1 1 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 19 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Lymphoma 6 Sarcoma, Synovial 5 Rhabdomyosarcoma 5 Neurofibrosarcoma 5 Malignant mesenchymal tumor 5 Lymphoma, Large B-Cell, Diffuse 5 Liposarcoma 5 Leukemia 5 Leiomyosarcoma 5 Histiocytoma, Malignant Fibrous 5 Hemangiosarcoma 5 Fibrosarcoma 5 Ovarian Neoplasms 4 Neuroectodermal Tumors, Primitive, Peripheral 4 Lung Neoplasms 4 Hemangiopericytoma, Malignant 4 Carcinoma, Non-Small-Cell Lung 4 Testicular Neoplasms 3 Teratoma 3 Neoplasm Metastasis 3 Hodgkin Disease 3 Uterine Cervical Neoplasms 2 Testicular Germ Cell Tumor 2 Seminoma 2 Sarcoma, Ewing 2 Sarcoma, Endometrial Stromal 2 Sarcoma, Alveolar Soft Part 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

Rituximab 10 pirtobrutinib 4 ibrutinib 4 Vincristine 3 Doxorubicin 3 zanubrutinib 2 Prednisone 2 Cytarabine 2 Cyclophosphamide 2 venetoclax 1 tositumomab I-131 1 etoposide phosphate 1 cirmtuzumab 1 axicabtagene ciloleucel 1 acalabrutinib 1 VAP-cyclo protocol 1 Radiotherapy 1 Methotrexate 1 Ifosfamide 1 Gemcitabine 1 Etoposide 1 Drug Therapy 1 Dexamethasone 1 Cisplatin 1 Carboplatin 1 Calcium Dobesilate 1 CEOP protocol 1 1 Bevacizumab 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06230224 2026-02-06

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡